Source: China Intellectual Property News

Editor's note: Creativity and innovation changes people’s life and intellectual property wins the future. On Dec. 13, the awarded projects of the 19th Chinese Patent Award were announced in Beijing, capturing much public attention. Among these achievements representing the highest level of intellectual property and innovation in China, 20 Gold Awards of Chinese Patent and 5 Gold Awards of Chinese Appearance Design especially grabbed the limelight. Since the implementation of these patents till the end of 2016, newly increased sales have reached 93.9 billion yuan, newly increased profits 9.6 billion yuan, and newly increased exports 24.4 billion yuan, becoming a crucial part of people's growing needs for a better life.

Original medicine to tackle tricky problems in cancer treatment

Malignant tumor, a major "killer" that threatens the health of human beings, is not only difficult to treat, but also a big burden for patients due to the costly drugs. In addition, the existing drugs are mostly non-selective inhibitors, highly toxic with severe side effect. To this end, Shenzhen Chipscreen Biosciences Co., Ltd. (hereinafter referred to as Chipscreen Biosciences) developed "benzamide histone deacetylase inhibitors and their pharmaceutical preparations with differentiation and antiproliferative activities" (Patent No.:ZL03139760.3) that solved tricky problems in treatment with existing drugs, broke the record of overseas zero-authorization of original drugs in China, and filled the blank in the industry.

In 2015, the patented core compound chidamide was officially launched with its first indication in peripheral T-cell lymphoma. The launch of chidamide not only fulfilled the urgent need in clinical application in China, but also solved the passive situation of waiting for introduction of newly invented drugs from foreign pharmaceutical companies. It is worth mentioning that the price of the drug is only 1/10 of imported ones, greatly relieving the economic burden on patients. Compared with traditional non-selective inhibitors, the drug also features exceptional curative effect, low toxicity, etc. 

According to the introduction, in 2006, centered on the patent, Chipscreen Biosciences granted patent license to a US company abroad, which pioneered China's original drug license-out to developed countries. In 2010, chidamide was officially approved by the US Food and Drug Administration (FDA) for clinical trial study, and was the first small molecule anti-tumor drug invented in China that was granted to access to clinical research in the United States. Moreover, the drug was rated as the most clinically valuable innovative drug in 2016 by the Chinese Academy of Medical Sciences.

Comments: Attached importance to patents is one of the reasons that Chipscreen Biosciences constantly develops and grows. With 16 years of innovation, Chipscreen Biosciences not only harvested innovative products one after another, but also held 52 patents. Intellectual property rights are escorting the innovation and development of enterprises.